NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Ostentus Therapeutics, Inc., announced today that it has entered into a second Sponsored Research Agreement with City of Hope, one of the largest cancer research and treatment organizations in the United States, to conduct preclinical research on OST compounds, which could be used as future therapies for leukemia and other cancers.